Sunshine Guojian Pharmaceutical Shanghai Co Ltd
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment;… Read more
Sunshine Guojian Pharmaceutical Shanghai Co Ltd (688336) - Net Assets
Latest net assets as of September 2025: CN¥5.86 Billion CNY
Based on the latest financial reports, Sunshine Guojian Pharmaceutical Shanghai Co Ltd (688336) has net assets worth CN¥5.86 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥8.81 Billion) and total liabilities (CN¥2.95 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥5.86 Billion |
| % of Total Assets | 66.49% |
| Annual Growth Rate | 15.04% |
| 5-Year Change | 22.49% |
| 10-Year Change | 123.8% |
| Growth Volatility | 17.29 |
Sunshine Guojian Pharmaceutical Shanghai Co Ltd - Net Assets Trend (2006–2024)
This chart illustrates how Sunshine Guojian Pharmaceutical Shanghai Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sunshine Guojian Pharmaceutical Shanghai Co Ltd (2006–2024)
The table below shows the annual net assets of Sunshine Guojian Pharmaceutical Shanghai Co Ltd from 2006 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.54 Billion | +13.49% |
| 2023-12-31 | CN¥4.88 Billion | +6.07% |
| 2022-12-31 | CN¥4.60 Billion | +1.33% |
| 2021-12-31 | CN¥4.54 Billion | +0.41% |
| 2020-12-31 | CN¥4.52 Billion | +55.68% |
| 2019-12-31 | CN¥2.90 Billion | -11.37% |
| 2018-12-31 | CN¥3.28 Billion | +12.34% |
| 2017-12-31 | CN¥2.92 Billion | +14.41% |
| 2016-12-31 | CN¥2.55 Billion | +3.03% |
| 2015-12-31 | CN¥2.47 Billion | +12.18% |
| 2014-12-31 | CN¥2.21 Billion | +11.04% |
| 2013-12-31 | CN¥1.99 Billion | +29.07% |
| 2012-12-31 | CN¥1.54 Billion | +20.16% |
| 2011-12-31 | CN¥1.28 Billion | +21.55% |
| 2010-12-31 | CN¥1.05 Billion | +58.25% |
| 2009-12-31 | CN¥665.80 Million | +27.06% |
| 2008-12-31 | CN¥523.99 Million | +13.02% |
| 2007-12-31 | CN¥463.64 Million | +4.24% |
| 2006-12-31 | CN¥444.77 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sunshine Guojian Pharmaceutical Shanghai Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 257233593575.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥2.33 Billion | 41.85% |
| Common Stock | CN¥616.79 Million | 11.08% |
| Other Components | CN¥2.62 Billion | 47.07% |
| Total Equity | CN¥5.57 Billion | 100.00% |
Sunshine Guojian Pharmaceutical Shanghai Co Ltd Competitors by Market Cap
The table below lists competitors of Sunshine Guojian Pharmaceutical Shanghai Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TI FLUID SYSTEMS LS-01
F:TI1
|
$723.58 Million |
|
Montrose Environmental Grp
NYSE:MEG
|
$724.07 Million |
|
Enghouse Systems Limited
PINK:EGHSF
|
$724.43 Million |
|
CREDITACCESS GRAMEEN LIMITED
NSE:CREDITACC
|
$724.43 Million |
|
Henan Senyuan Electric Co Ltd
SHE:002358
|
$722.88 Million |
|
Turkiye Vakiflar Bankasi TAO
IS:VAKBN
|
$722.86 Million |
|
Ningbo Tech-Bank Co Ltd
SHE:002124
|
$722.58 Million |
|
Empire State Realty Trust Inc
NYSE:ESRT
|
$722.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sunshine Guojian Pharmaceutical Shanghai Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,896,134,900 to 5,567,642,097, a change of 671,507,197 (13.7%).
- Net income of 704,579,100 contributed positively to equity growth.
- Dividend payments of 51,193,200 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥704.58 Million | +12.65% |
| Dividends Paid | CN¥51.19 Million | -0.92% |
| Other Changes | CN¥18.12 Million | +0.33% |
| Total Change | CN¥- | 13.72% |
Book Value vs Market Value Analysis
This analysis compares Sunshine Guojian Pharmaceutical Shanghai Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.30x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 27.40x to 6.30x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | CN¥2.08 | CN¥56.87 | x |
| 2011-12-31 | CN¥2.29 | CN¥56.87 | x |
| 2012-12-31 | CN¥2.83 | CN¥56.87 | x |
| 2013-12-31 | CN¥3.39 | CN¥56.87 | x |
| 2014-12-31 | CN¥3.81 | CN¥56.87 | x |
| 2015-12-31 | CN¥4.31 | CN¥56.87 | x |
| 2016-12-31 | CN¥4.86 | CN¥56.87 | x |
| 2017-12-31 | CN¥5.57 | CN¥56.87 | x |
| 2018-12-31 | CN¥6.27 | CN¥56.87 | x |
| 2019-12-31 | CN¥4.65 | CN¥56.87 | x |
| 2020-12-31 | CN¥7.31 | CN¥56.87 | x |
| 2021-12-31 | CN¥7.37 | CN¥56.87 | x |
| 2022-12-31 | CN¥7.47 | CN¥56.87 | x |
| 2023-12-31 | CN¥7.98 | CN¥56.87 | x |
| 2024-12-31 | CN¥9.03 | CN¥56.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sunshine Guojian Pharmaceutical Shanghai Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.65%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 59.03%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 1.07x
- Recent ROE (12.65%) is above the historical average (9.07%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -7.08% | -91.17% | 0.07x | 1.16x | CN¥-75.98 Million |
| 2007 | 3.74% | 18.74% | 0.17x | 1.16x | CN¥-29.03 Million |
| 2008 | 11.92% | 39.17% | 0.26x | 1.18x | CN¥10.04 Million |
| 2009 | 16.57% | 44.98% | 0.33x | 1.11x | CN¥43.73 Million |
| 2010 | 15.90% | 45.64% | 0.30x | 1.15x | CN¥58.08 Million |
| 2011 | 16.63% | 41.31% | 0.30x | 1.34x | CN¥78.23 Million |
| 2012 | 17.86% | 43.13% | 0.30x | 1.36x | CN¥113.05 Million |
| 2013 | 17.04% | 40.57% | 0.32x | 1.31x | CN¥121.95 Million |
| 2014 | 10.92% | 27.38% | 0.34x | 1.18x | CN¥17.87 Million |
| 2015 | 9.56% | 24.02% | 0.34x | 1.17x | CN¥-9.60 Million |
| 2016 | 10.90% | 27.89% | 0.33x | 1.17x | CN¥22.19 Million |
| 2017 | 13.64% | 35.23% | 0.33x | 1.17x | CN¥103.75 Million |
| 2018 | 11.48% | 32.36% | 0.31x | 1.15x | CN¥47.54 Million |
| 2019 | 7.99% | 19.47% | 0.35x | 1.16x | CN¥-57.51 Million |
| 2020 | -4.83% | -33.20% | 0.13x | 1.10x | CN¥-667.77 Million |
| 2021 | 0.40% | 1.94% | 0.19x | 1.08x | CN¥-436.10 Million |
| 2022 | 1.07% | 5.97% | 0.16x | 1.11x | CN¥-411.29 Million |
| 2023 | 6.02% | 29.05% | 0.19x | 1.08x | CN¥-195.00 Million |
| 2024 | 12.65% | 59.03% | 0.20x | 1.07x | CN¥147.81 Million |
Industry Comparison
This section compares Sunshine Guojian Pharmaceutical Shanghai Co Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sunshine Guojian Pharmaceutical Shanghai Co Ltd (688336) | CN¥5.86 Billion | -7.08% | 0.50x | $723.02 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |